Research programme: anticancer therapeutics - AEterna Zentaris

Drug Profile

Research programme: anticancer therapeutics - AEterna Zentaris

Alternative Names: D 87264; D-81050; D-82318; Microtubule inhibitors - AEterna Zentaris; Tubulin polymerisation inhibitors - AEterna Zentaris; ZEN 011; ZEN-014

Latest Information Update: 13 May 2011

Price : $50

At a glance

  • Originator Zentaris
  • Developer AEterna Zentaris Inc
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cytoskeletal protein inhibitors; KIF11 protein inhibitors; Mitosis inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 13 May 2011 Discontinued - Preclinical for Solid tumours in Germany (PO)
  • 07 Nov 2007 Three compounds have been selected for further preclinical development
  • 06 Mar 2006 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top